This study proposed a combination therapy involving the exogenous overexpression of hENT1 and the administration of miR-143 mimic to increase GEM uptake and decrease glycolysis in tumor cells, and assessed the efficacy of this therapy to reduce GEM resistance in vitro and in an animal model of TNBC. The gene discussed is SLC29A1; the disease is neoplasm.